Loading...
•
Sep 30, 2022
Zai Lab Q3 2022 Earnings Report
Reported a 33% increase in revenue y-o-y and a 19% increase q-o-q, driven by ZEJULA, and strengthened its leadership in women's cancer treatment with a regional collaboration for TIVDAK.
Key Takeaways
Zai Lab reported a strong third quarter with a new regional collaboration, significant revenue growth across commercial products, and progress towards achieving its 2022 corporate priorities. Total revenues were $57.5 million, a 33% increase year-over-year.
Revenue of $57.5 million for the third quarter of 2022, representing a 33% increase y-o-y and a 19% increase q-o-q; continued revenue growth led by ZEJULA
Regional strategic collaboration for TIVDAK strengthens Zai Lab’s leadership in developing and providing access to medicine to treat women’s cancer in China
Strong balance sheet with a cash position of $1.12 billion
Agreement with the NMPA on the development plan for a bridging study for KarXT in schizophrenia in China.
Zai Lab
Zai Lab
Zai Lab Revenue by Segment
Revenue by Segment
ZEJULA Revenue
CapyFin.comNUZYRA Revenue
CapyFin.com Forward Guidance
We expect our net product revenue to exceed cost of goods sold and commercial expenses in 2023.
Revenue & Expenses
Visualization of income flow from segment revenue to net income